{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T17:48:51Z","timestamp":1780508931100,"version":"3.54.1"},"reference-count":68,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T00:00:00Z","timestamp":1774310400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T00:00:00Z","timestamp":1774310400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1007\/s12325-026-03559-7","type":"journal-article","created":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T06:59:01Z","timestamp":1774335541000},"page":"1983-2000","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Evidence-Based Positioning of Sodium-Glucose Co-transporter\u00a02 Inhibitors and Glucagon-Like Peptide\u00a01 Receptor Agonists in the Management of Chronic Kidney Disease with Type\u00a02 Diabetes and Overweight or Obesity: A Systematic Literature Review"],"prefix":"10.1007","volume":"43","author":[{"given":"Yehuda","family":"Handelsman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice Y. Y.","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gian Paolo","family":"Fadini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pam","family":"Kushner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrice","family":"Bonnet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Fioretto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Kadowaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naresh","family":"Kanumilli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Cos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Frese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linong","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Molly","family":"Murton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Foulcer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Surendra","family":"Pentakota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Rossing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,24]]},"reference":[{"issue":"4s","key":"3559_CR1","first-page":"S117","volume":"105","author":"KDIGO","year":"2024","unstructured":"KDIGO. Clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. 2024;105(4s):S117\u2013s314.","journal-title":"Kidney Int"},{"key":"3559_CR2","unstructured":"Kidney Research UK. Kidney disease: a UK public health emergency. 2023. https:\/\/www.kidneyresearchuk.org\/wp-content\/uploads\/2023\/06\/Economics-of-Kidney-Disease-full-report_accessible.pdf. Accessed May\u00a02025."},{"issue":"10","key":"3559_CR3","volume":"14","author":"R Prasad","year":"2022","unstructured":"Prasad R, Jha RK, Keerti A. Chronic kidney disease: its relationship with obesity. Cureus. 2022;14(10):e30535.","journal-title":"Cureus"},{"issue":"2","key":"3559_CR4","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1038\/s41440-022-01114-9","volume":"46","author":"K Kohagura","year":"2023","unstructured":"Kohagura K. The public health impact of hypertension and diabetes: a powerful tag team for the development of chronic kidney disease. Hypertens Res. 2023;46(2):339\u201340.","journal-title":"Hypertens Res"},{"key":"3559_CR5","unstructured":"National Institute for Health and Care Excellence. Chronic kidney disease: what are the complications? 2024. https:\/\/cks.nice.org.uk\/topics\/chronic-kidney-disease\/background-information\/complications\/. Accessed May\u00a02025."},{"key":"3559_CR6","unstructured":"American Diabetes Association. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes. 2025. https:\/\/diabetesjournals.org\/care\/article\/48\/Supplement_1\/S239\/157554\/11-Chronic-Kidney-Disease-and-Risk-Management. Accessed May\u00a02025."},{"issue":"10313","key":"3559_CR7","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1016\/S0140-6736(21)02188-7","volume":"398","author":"S Del Prato","year":"2021","unstructured":"Del Prato S, Kahn SE, Pavo I, et al. Tirzepatide versus insulin glargine in type\u00a02 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase\u00a03 trial. Lancet. 2021;398(10313):1811\u201324.","journal-title":"Lancet"},{"issue":"1","key":"3559_CR8","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1186\/s12933-023-01964-8","volume":"22","author":"J Smeijer","year":"2023","unstructured":"Smeijer J, Kohan D, Rossing P, et al. Insulin resistance, kidney outcomes and effects of the endothelin receptor antagonist atrasentan in patients with type\u00a02 diabetes and chronic kidney disease. Cardiovasc Diabetol. 2023;22(1):251.","journal-title":"Cardiovasc Diabetol"},{"issue":"6","key":"3559_CR9","doi-asserted-by":"publisher","first-page":"2128","DOI":"10.1111\/dom.15518","volume":"26","author":"S Bornstein","year":"2024","unstructured":"Bornstein S, de Zeeuw D, Heerspink H, et al. Aldosterone synthase inhibitor (BI 690517) therapy for people with diabetes and albuminuric chronic kidney disease: a multicentre, randomized, double-blind, placebo-controlled, phase\u00a0I trial. Diabetes Obes Metab. 2024;26(6):2128\u201338.","journal-title":"Diabetes Obes Metab"},{"key":"3559_CR10","unstructured":"Zoungas S et al. Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type\u00a02 diabetes and atherosclerotic cardiovascular disease: SURPASS-CVOT; The evolution of renal status in participants on tirzepatide versus dulaglutide of the SURPASS-CVOT. Presented at EASD, Vienna, 2025."},{"issue":"15","key":"3559_CR11","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","volume":"383","author":"H Heerspink","year":"2020","unstructured":"Heerspink H, Stef\u00e1nsson B, Correa-Rotter R, et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383(15):1436\u201346.","journal-title":"N Engl J Med"},{"issue":"2","key":"3559_CR12","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1056\/NEJMoa2204233","volume":"388","author":"W Herrington","year":"2023","unstructured":"Herrington W, Staplin N, Wanner C, et al. Empagliflozin in patients with chronic kidney disease. N Engl J Med. 2023;388(2):117\u201327.","journal-title":"N Engl J Med"},{"issue":"24","key":"3559_CR13","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","volume":"380","author":"V Perkovic","year":"2019","unstructured":"Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and renal outcomes in type\u00a02 diabetes and nephropathy. N Engl J Med. 2019;380(24):2295\u2013306.","journal-title":"N Engl J Med"},{"issue":"2","key":"3559_CR14","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1056\/NEJMoa2403347","volume":"391","author":"V Perkovic","year":"2024","unstructured":"Perkovic V, Tuttle KR, Rossing P, et al. Effects of semaglutide on chronic kidney disease in patients with type\u00a02 diabetes. N Engl J Med. 2024;391(2):109\u201321.","journal-title":"N Engl J Med"},{"issue":"6","key":"3559_CR15","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1016\/j.kint.2024.08.023","volume":"106","author":"V Selvarajah","year":"2024","unstructured":"Selvarajah V, Robertson D, Hansen L, et al. A randomized phase\u00a02b trial examined the effects of the glucagon-like peptide-1 and glucagon receptor agonist cotadutide on kidney outcomes in patients with diabetic kidney disease. Kidney Int. 2024;106(6):1170\u201380.","journal-title":"Kidney Int"},{"key":"3559_CR16","unstructured":"AstraZeneca. Farxiga phase\u00a0III DAPA-CKD trial will be stopped early after overwhelming efficacy in patients with chronic kidney disease.  2020. https:\/\/www.astrazeneca.com\/media-centre\/press-releases\/2020\/farxiga-phase-iii-dapa-ckd-trial-will-be-stopped-early-after-overwhelming-efficacy-in-patients-with-chronic-kidney-disease.html#. Accessed Oct 2025."},{"issue":"4","key":"3559_CR17","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1603827","volume":"375","author":"S Marso","year":"2016","unstructured":"Marso S, Daniels G, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type\u00a02 diabetes. N Engl J Med. 2016;375(4):311\u201322.","journal-title":"N Engl J Med"},{"issue":"10193","key":"3559_CR18","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","volume":"394","author":"H Gerstein","year":"2019","unstructured":"Gerstein H, Colhoun H, Dagenais G, et al. Dulaglutide and cardiovascular outcomes in type\u00a02 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet. 2019;394(10193):121\u201330.","journal-title":"Lancet"},{"issue":"10","key":"3559_CR19","doi-asserted-by":"publisher","first-page":"2849","DOI":"10.1038\/s41591-024-03133-0","volume":"30","author":"J Mann","year":"2024","unstructured":"Mann J, Rossing P, Bakris G, et al. Effects of semaglutide with and without concomitant SGLT2 inhibitor use in participants with type\u00a02 diabetes and chronic kidney disease in the FLOW trial. Nat Med. 2024;30(10):2849\u201356.","journal-title":"Nat Med"},{"key":"3559_CR20","volume-title":"Systematic Reviews: CRD\u2019s guidance for undertaking reviews in health care","author":"Centre for Reviews and Dissemination","year":"2008","unstructured":"Centre for Reviews and Dissemination. Systematic Reviews: CRD\u2019s guidance for undertaking reviews in health care. York: Centre for Reviews and Dissemination, University of York; 2008."},{"issue":"8","key":"3559_CR21","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1111\/dom.14741","volume":"24","author":"YH Dong","year":"2022","unstructured":"Dong YH, Chang CH, Lin JW, Yang WS, Wu LC, Toh S. Comparative cardiovascular effectiveness of glucagon-like peptide-1 receptor agonists versus sodium-glucose cotransporter-2 inhibitors in patients with type\u00a02 diabetes: a population-based cohort study. Diabetes Obes Metab. 2022;24(8):1623\u201337.","journal-title":"Diabetes Obes Metab"},{"issue":"8","key":"3559_CR22","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1016\/j.jacc.2024.06.016","volume":"84","author":"D Edmonston","year":"2024","unstructured":"Edmonston D, Mulder H, Lydon E, et al. Kidney and cardiovascular effectiveness of SGLT2 Inhibitors vs GLP-1 receptor agonists in type\u00a02 diabetes. J Am Coll Cardiol. 2024;84(8):696\u2013708.","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"3559_CR23","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1016\/j.kint.2023.11.025","volume":"105","author":"E Fu","year":"2024","unstructured":"Fu E, Mastrorilli J, Bykov K, et al. A population-based cohort defined risk of hyperkalemia after initiating SGLT-2 inhibitors, GLP1 receptor agonists or DPP-4 inhibitors to patients with chronic kidney disease and type\u00a02 diabetes. Kidney Int. 2024;105(3):618\u201328.","journal-title":"Kidney Int"},{"issue":"10","key":"3559_CR24","first-page":"10","volume":"35","author":"S Hartsell","year":"2024","unstructured":"Hartsell S, Sarwal A, Singh R, et al. SGLT2 inhibitors are associated with lower risk of CKD progression in type\u00a02 diabetes (T2D) than glucagon-like peptide 1 receptor agonists (GLP-1\u00a0RAs): an emulated clinical trial: FR-PO319. J Am Soc Nephrol. 2024;35(10):10\u2013681.","journal-title":"J Am Soc Nephrol"},{"issue":"9","key":"3559_CR25","doi-asserted-by":"publisher","first-page":"2493","DOI":"10.1210\/clinem\/dgac402","volume":"107","author":"F-C Hsiao","year":"2022","unstructured":"Hsiao F-C, Yen K-C, Chao T-F, Chen S-W, Chan Y-H, Chu P-H. New-onset atrial fibrillation in patients with type\u00a02 diabetes treated with novel glucose-lowering therapies. J Clin Endocrinol Metab. 2022;107(9):2493\u20139.","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"3559_CR26","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s12933-024-02150-0","volume":"23","author":"PT Htoo","year":"2024","unstructured":"Htoo PT, Tesfaye H, Schneeweiss S, et al. Cardiorenal effectiveness of empagliflozin vs. glucagon-like peptide-1 receptor agonists: final-year results from the EMPRISE study. Cardiovasc Diabetol. 2024;23(1):57.","journal-title":"Cardiovasc Diabetol"},{"issue":"3","key":"3559_CR27","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.0946","volume":"7","author":"J-C Hu","year":"2024","unstructured":"Hu J-C, Shao S-C, Tsai H-T, Chuang AT-M, Liu K-H, Lai EC-C. Use of SGLT2 inhibitors vs GLP-1\u00a0RAs and anemia in patients with diabetes and CKD. JAMA Netw Open. 2024;7(3):e240946-e.","journal-title":"JAMA Netw Open"},{"issue":"5","key":"3559_CR28","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1093\/ehjcvp\/pvad033","volume":"9","author":"YK J\u00fal\u00edusd\u00f3ttir","year":"2023","unstructured":"J\u00fal\u00edusd\u00f3ttir YK, Halili A, Coronel R, et al. Sodium-glucose cotransporter-2 inhibitors compared with glucagon-like-peptide-1 receptor agonists and out-of-hospital cardiac arrest in type\u00a02 diabetes: a nationwide nested case-control study. Eur Heart J-Cardiovasc Pharmacother. 2023;9(5):437\u201343.","journal-title":"Eur Heart J-Cardiovasc Pharmacother"},{"issue":"3","key":"3559_CR29","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1053\/j.ajkd.2025.03.016","volume":"86","author":"Y-C Lee","year":"2025","unstructured":"Lee Y-C, Wu L-C, Wu V-C, Chang C-H. Comparative effectiveness of glucagon-like peptide-1 receptor agonists and sodium\/glucose cotransporter\u00a02 inhibitors in preventing chronic kidney failure and mortality in patients with type\u00a02 diabetes and CKD. Am J Kidney Dis. 2025;86(3):301-313.e1.","journal-title":"Am J Kidney Dis"},{"key":"3559_CR30","doi-asserted-by":"publisher","unstructured":"McCormick T, Kramer J, Liles EG, Amos Q, Martin JP, Adams JL. Cardiovascular and mortality benefits of sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide 1 receptor agonists as third-step glucose-lowering medicine in patients with type\u00a02 diabetes: a retrospective cohort analysis. BMJ Open Diabetes Res Care. 2024;12(3). https:\/\/doi.org\/10.1136\/bmjdrc-2023-003792.","DOI":"10.1136\/bmjdrc-2023-003792"},{"issue":"10S","key":"3559_CR31","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.20244hrvkhs9","volume":"35","author":"I Nawaz","year":"2024","unstructured":"Nawaz I, Mallipattu SK. Safety profile of SGLT2 inhibitor and glucagon-like peptide 1 receptor agonist (GLP-1\u00a0RA) use in patients with CKD: FR-PO1126. J Am Soc Nephrol. 2024;35(10S):10.1681.","journal-title":"J Am Soc Nephrol"},{"issue":"3","key":"3559_CR32","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1001\/jamainternmed.2023.7660","volume":"184","author":"J Paik","year":"2024","unstructured":"Paik J, Tesfaye H, Curhan G, Zakoul H, Wexler D, Patorno E. Sodium-glucose cotransporter\u00a02 inhibitors and nephrolithiasis risk in patients with type\u00a02 diabetes. JAMA Intern Med. 2024;184(3):265\u201374.","journal-title":"JAMA Intern Med"},{"issue":"4","key":"3559_CR33","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1111\/dom.15427","volume":"26","author":"J Rhee","year":"2024","unstructured":"Rhee J, Han J, Montez-Rath M, Chertow GM. Comparative effectiveness of sodium-glucose cotransporter-2 inhibitors versus glucagon-like peptide-1 receptor agonists in patients with type\u00a02 diabetes and mild\/moderate chronic kidney disease. Diabetes Obes Metab. 2024;26(4):1273\u201381.","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"3559_CR34","first-page":"702","volume":"66","author":"P Rossing","year":"2023","unstructured":"Rossing P, Fioretto P, Clark AJ, Jensen A, Nazal NB, Tuttle KR. Comparative effectiveness of GLP-1 receptor agonists versus SGLT2 inhibitors in patients with type\u00a02 diabetes and moderate chronic kidney disease. Diabetologia. 2023;66(1):702.","journal-title":"Diabetologia"},{"issue":"11","key":"3559_CR35","doi-asserted-by":"publisher","first-page":"2585","DOI":"10.1007\/s00125-024-06251-z","volume":"67","author":"G Fadini","year":"2024","unstructured":"Fadini G, Longato E, Morieri M, et al. Comparative renal outcomes of matched cohorts of patients with type\u00a02 diabetes receiving SGLT2 inhibitors or GLP-1 receptor agonists under routine care. Diabetologia. 2024;67(11):2585\u201397.","journal-title":"Diabetologia"},{"issue":"10","key":"3559_CR36","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.37606","volume":"5","author":"P Htoo","year":"2022","unstructured":"Htoo P, Tesfaye H, Schneeweiss S, et al. Comparative effectiveness of empagliflozin vs liraglutide or sitagliptin in older adults with diverse patient characteristics. JAMA Netw Open. 2022;5(10):e2237606.","journal-title":"JAMA Netw Open"},{"issue":"6","key":"3559_CR37","doi-asserted-by":"publisher","first-page":"1758","DOI":"10.1111\/dom.15033","volume":"25","author":"A van der Aart- Beek","year":"2023","unstructured":"van der Aart- Beek A, Apperloo E, Jongs N, et al. Albuminuria-lowering effect of dapagliflozin, exenatide, and their combination in patients with type\u00a02 diabetes: a randomized cross-over clinical study. Diabetes Obes Metab. 2023;25(6):1758\u201368.","journal-title":"Diabetes Obes Metab"},{"issue":"3","key":"3559_CR38","doi-asserted-by":"publisher","first-page":"602","DOI":"10.2337\/dc22-1514","volume":"46","author":"J Beernink","year":"2023","unstructured":"Beernink J, Persson F, Jongs N, et al. Efficacy of dapagliflozin by baseline diabetes medications: a prespecified analysis from the DAPA-CKD study. Diabetes Care. 2023;46(3):602\u20137.","journal-title":"Diabetes Care"},{"issue":"1","key":"3559_CR39","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1186\/s12933-025-02737-1","volume":"24","author":"N Chaiyakunapruk","year":"2025","unstructured":"Chaiyakunapruk N, Tan X, Liang Y, Guevarra M, Xie L, Cheng AYY. Real-world effectiveness of adding newer generation GLP-1RA to SGLT2i in type\u00a02 diabetes. Cardiovasc Diabetol. 2025;24(1):177.","journal-title":"Cardiovasc Diabetol"},{"issue":"10","key":"3559_CR40","doi-asserted-by":"publisher","first-page":"4674","DOI":"10.1111\/dom.15834","volume":"26","author":"L Chu","year":"2024","unstructured":"Chu L, Bradley RM, Auerbach P, Abitbol A. Real-world impact of adding a glucagon-like peptide-1 receptor agonist compared with basal insulin on metabolic targets in adults living with type\u00a02 diabetes and chronic kidney disease already treated with a sodium-glucose co-transporter-2 inhibitor: the Impact GLP-1 CKD study. Diabetes Obes Metab. 2024;26(10):4674\u201383.","journal-title":"Diabetes Obes Metab"},{"issue":"11","key":"3559_CR41","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1111\/jdi.13877","volume":"13","author":"K Tsuchida","year":"2022","unstructured":"Tsuchida K, Taneda S, Yokota I, et al. The renoprotective effect of once-weekly GLP-1 receptor agonist dulaglutide on progression of nephropathy in Japanese patients with type\u00a02 diabetes and moderate to severe chronic kidney disease (JDDM67). J Diabetes Investig. 2022;13(11):1834\u201341.","journal-title":"J Diabetes Investig"},{"issue":"Supplement_1","key":"3559_CR42","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfae069.699","volume":"39","author":"Q Yang","year":"2024","unstructured":"Yang Q, Liu F. # 995 effectiveness of semaglutide once weekly as add-on to SGLT-2Is in T2DM and CKD: a single-center observational study with body composition assessment. Nephrol Dial Transpl. 2024;39(Supplement_1):gfae069-0699-995.","journal-title":"Nephrol Dial Transpl"},{"issue":"23","key":"3559_CR43","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1161\/CIRCULATIONAHA.125.074545","volume":"151","author":"N Marx","year":"2025","unstructured":"Marx N, Deanfield J, Mann J, et al. Oral semaglutide and cardiovascular outcomes in people with type\u00a02 diabetes, according to SGLT2i use: prespecified analyses of the SOUL randomized trial. Circulation. 2025;151(23):1639\u201350.","journal-title":"Circulation"},{"issue":"8","key":"3559_CR44","doi-asserted-by":"publisher","first-page":"3248","DOI":"10.1111\/dom.15652","volume":"26","author":"S Tsukamoto","year":"2024","unstructured":"Tsukamoto S, Kobayashi K, Toyoda M, et al. Effect of preceding drug therapy on the renal and cardiovascular outcomes of combined sodium-glucose cotransporter-2 inhibitor and glucagon-like peptide-1 receptor agonist treatment in patients with type\u00a02 diabetes and chronic kidney disease. Diabetes Obes Metab. 2024;26(8):3248\u201360.","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"3559_CR45","doi-asserted-by":"publisher","DOI":"10.3390\/biom15010039","volume":"15","author":"I Bellos","year":"2025","unstructured":"Bellos I, Marinaki S, Lagiou P, Benetou V. Comparative efficacy and safety of cardio-renoprotective pharmacological interventions in chronic kidney disease: an umbrella review of network meta-analyses and a multicriteria decision analysis. Biomolecules. 2025;15(1):39.","journal-title":"Biomolecules"},{"key":"3559_CR46","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.1003263","volume":"13","author":"Y Li","year":"2022","unstructured":"Li Y, Hu Y, Huyan X, et al. Comparison of efficacy and safety of three novel hypoglycemic agents in patients with severe diabetic kidney disease: a systematic review and network meta-analysis of randomized controlled trials. Front Endocrinol (Lausanne). 2022;13:1003263.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"6","key":"3559_CR47","doi-asserted-by":"publisher","first-page":"1614","DOI":"10.1111\/dom.15009","volume":"25","author":"BN Nguyen","year":"2023","unstructured":"Nguyen BN, Nguyen L, Mital S, Bugden S, Nguyen HV. Comparative efficacy of sodium-glucose co-transporter-2 inhibitors, glucagon-like peptide-1 receptor agonists and non-steroidal mineralocorticoid receptor antagonists in chronic kidney disease and type\u00a02 diabetes: a systematic review and network meta-analysis. Diabetes Obes Metab. 2023;25(6):1614\u201323.","journal-title":"Diabetes Obes Metab"},{"key":"3559_CR48","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12933-020-01197-z","volume":"20","author":"T Yamada","year":"2021","unstructured":"Yamada T, Wakabayashi M, Bhalla A, et al. Cardiovascular and renal outcomes with SGLT-2 inhibitors versus GLP-1 receptor agonists in patients with type\u00a02 diabetes mellitus and chronic kidney disease: a systematic review and network meta-analysis. Cardiovasc Diabetol. 2021;20:1\u201313.","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"3559_CR49","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-022-01676-5","volume":"21","author":"Y Zhang","year":"2022","unstructured":"Zhang Y, Jiang L, Wang J, et al. Network meta-analysis on the effects of finerenone versus SGLT2 inhibitors and GLP-1 receptor agonists on cardiovascular and renal outcomes in patients with type\u00a02 diabetes mellitus and chronic kidney disease. Cardiovasc Diabetol. 2022;21(1):232.","journal-title":"Cardiovasc Diabetol"},{"key":"3559_CR50","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2023.110592","volume":"198","author":"Q Yang","year":"2023","unstructured":"Yang Q, Lang Y, Yang W, et al. Efficacy and safety of drugs for people with type\u00a02 diabetes mellitus and chronic kidney disease on kidney and cardiovascular outcomes: a systematic review and network meta-analysis of randomized controlled trials. Diabetes Res Clin Pract. 2023;198:110592.","journal-title":"Diabetes Res Clin Pract"},{"issue":"8","key":"3559_CR51","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/S2213-8587(24)00155-4","volume":"12","author":"EM Apperloo","year":"2024","unstructured":"Apperloo EM, Neuen BL, Fletcher RA, et al. Efficacy and safety of SGLT2 inhibitors with and without glucagon-like peptide 1 receptor agonists: a SMART-C collaborative meta-analysis of randomised controlled trials. Lancet Diabetes Endocrinol. 2024;12(8):545\u201357.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"3559_CR52","doi-asserted-by":"publisher","first-page":"1517272","DOI":"10.3389\/fphar.2025.1517272","volume":"16","author":"J Guo","year":"2025","unstructured":"Guo J, Wei M, Zhang W, et al. Clinical efficacy and safety of sodium-glucose cotransporter protein-2 (SGLT-2) inhibitor, glucagon-like peptide-1 (GLP-1) receptor agonist, and finerenone in type\u00a02 diabetes mellitus with non-dialysis chronic kidney disease: a network meta-analysis of randomized clinical trials. Front Pharmacol. 2025;16:1517272.","journal-title":"Front Pharmacol"},{"issue":"supplement_1","key":"3559_CR53","doi-asserted-by":"publisher","first-page":"422-p","DOI":"10.2337\/db23-422-P","volume":"72","author":"K Kashima","year":"2023","unstructured":"Kashima K, Shimizu H, Yamada M. 422-P: GLP-1\u00a0RA should be used with SGLT2 inhibitor in people with rapidly progressive CKD. Diabetes. 2023;72(supplement_1):422-p.","journal-title":"Diabetes"},{"issue":"8","key":"3559_CR54","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1093\/ndt\/gfae010","volume":"39","author":"A Matus Gonzalez","year":"2024","unstructured":"Matus Gonzalez A, Evangelidis N, Howell M, et al. Outcomes for clinical trials involving adults with chronic kidney disease: a multinational Delphi survey involving patients, caregivers and health professionals. Nephrol Dial Transplant. 2024;39(8):1310\u201321.","journal-title":"Nephrol Dial Transplant"},{"issue":"23","key":"3559_CR55","doi-asserted-by":"publisher","first-page":"2148","DOI":"10.1093\/eurheartj\/ehaf167","volume":"46","author":"K Marx-Schutt","year":"2025","unstructured":"Marx-Schutt K, Cherney DZI, Jankowski J, Matsushita K, Nardone M, Marx N. Cardiovascular disease in chronic kidney disease. Eur Heart J. 2025;46(23):2148\u201360.","journal-title":"Eur Heart J"},{"issue":"4","key":"3559_CR56","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.31083\/j.rcm2204152","volume":"22","author":"A Kamdar","year":"2021","unstructured":"Kamdar A, Sykes R, Morrow A, Mangion K, Berry C. Cardiovascular outcomes of glucose lowering therapy in chronic kidney disease patients: a systematic review with meta-analysis. Rev Cardiovasc Med. 2021;22(4):1479\u201390.","journal-title":"Rev Cardiovasc Med"},{"issue":"19","key":"3559_CR57","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","volume":"375","author":"S Marso","year":"2016","unstructured":"Marso S, Bain S, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type\u00a02 diabetes. N Engl J Med. 2016;375(19):1834\u201344.","journal-title":"N Engl J Med"},{"issue":"17","key":"3559_CR58","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1016\/j.jacc.2024.08.004","volume":"84","author":"R Pratley","year":"2024","unstructured":"Pratley R, Tuttle K, Rossing P, et al. Effects of semaglutide on heart failure outcomes in diabetes and chronic kidney disease in the FLOW trial. J Am Coll Cardiol. 2024;84(17):1615\u201328.","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"3559_CR59","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2022-061807","volume":"13","author":"H Ma","year":"2023","unstructured":"Ma H, Lin Y-H, Dai L-Z, Lin C-S, Huang Y, Liu S-Y. Efficacy and safety of GLP-1 receptor agonists versus SGLT-2 inhibitors in overweight\/obese patients with or without diabetes mellitus: a systematic review and network meta-analysis. BMJ Open. 2023;13(3):e061807.","journal-title":"BMJ Open"},{"issue":"9","key":"3559_CR60","doi-asserted-by":"publisher","first-page":"2415","DOI":"10.1016\/j.ekir.2021.06.029","volume":"6","author":"A Arshad","year":"2021","unstructured":"Arshad A, Sarween N, Sharif A. Systematic review of cardiovascular outcome trials using new antidiabetic agents in CKD stratified by estimated GFR. Kidney Int Rep. 2021;6(9):2415\u201324.","journal-title":"Kidney Int Rep"},{"issue":"5","key":"3559_CR61","doi-asserted-by":"publisher","first-page":"771","DOI":"10.34067\/KID.0000000000000425","volume":"5","author":"A Upadhyay","year":"2024","unstructured":"Upadhyay A. SGLT2 inhibitors and kidney protection: mechanisms beyond tubuloglomerular feedback. Kidney360. 2024;5(5):771\u201382.","journal-title":"Kidney360"},{"issue":"3","key":"3559_CR62","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabet.2025.101641","volume":"51","author":"J Chen","year":"2025","unstructured":"Chen J, Cooper M, Coughlan M. Renoprotective mechanisms of glucagon-like peptide-1 receptor agonists. Diabetes Metab. 2025;51(3):101641.","journal-title":"Diabetes Metab"},{"issue":"1","key":"3559_CR63","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1080\/00325481.2021.2002616","volume":"134","author":"S Wharton","year":"2022","unstructured":"Wharton S, Davies M, Dicker D, et al. Managing the gastrointestinal side effects of GLP-1 receptor agonists in obesity: recommendations for clinical practice. Postgrad Med. 2022;134(1):14\u20139.","journal-title":"Postgrad Med"},{"key":"3559_CR64","doi-asserted-by":"publisher","first-page":"1010693","DOI":"10.3389\/fcvm.2022.1010693","volume":"9","author":"A Mascolo","year":"2022","unstructured":"Mascolo A, Di Napoli R, Balzano N, et al. Safety profile of sodium glucose co-transporter\u00a02 (SGLT2) inhibitors: a brief summary. Front Cardiovasc Med. 2022;9:1010693.","journal-title":"Front Cardiovasc Med"},{"issue":"11","key":"3559_CR65","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1016\/S2213-8587(22)00243-1","volume":"10","author":"H Heerspink","year":"2022","unstructured":"Heerspink H, Sattar N, Pavo I, et al. Effects of tirzepatide versus insulin glargine on kidney outcomes in type\u00a02 diabetes in the SURPASS-4 trial: post-hoc analysis of an open-label, randomised, phase\u00a03 trial. Lancet Diabetes Endocrinol. 2022;10(11):774\u201385.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"8","key":"3559_CR66","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.27258","volume":"7","author":"M Chuang","year":"2024","unstructured":"Chuang M, Chen J, Wang H, Jiang Z, Wu V. Clinical outcomes of tirzepatide or GLP-1 receptor agonists in individuals with type\u00a02 diabetes. JAMA Netw Open. 2024;7(8):e2427258.","journal-title":"JAMA Netw Open"},{"key":"3559_CR67","unstructured":"ClinicalTrials.gov. A study of Tirzepatide (LY3298176) compared with dulaglutide on major cardiovascular events in participants with type\u00a02 diabetes (SURPASS-CVOT). https:\/\/clinicaltrials.gov\/study\/NCT04255433#study-overview. Accessed Sept 2025."},{"key":"3559_CR68","unstructured":"Higgins J, Thomas J, Chandler J, et al. Cochrane Handbook for Systematic Reviews of Interventions version 6.2 (updated February 2021). Cochrane, 2021. www.training.cochrane.org\/handbook. Accessed May\u00a02025."}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03559-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-026-03559-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03559-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T10:24:38Z","timestamp":1778581478000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-026-03559-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,24]]},"references-count":68,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["3559"],"URL":"https:\/\/doi.org\/10.1007\/s12325-026-03559-7","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,24]]},"assertion":[{"value":"18 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Yehuda Handelsman: Received research grants, consultant & speaker honoraria from Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Corcept, Eli Lilly, Ionis, Merck, Novo Nordisk, Regeneron, Sanofi, Verdiva Bio; Alice Cheng: Received consulting and speaking honoraria from Abbott, Astellas, Aspen, AstraZeneca, Amgen, Bausch, Bayer, Biomea Fusion, Boehringer Ingelheim, Dexcom, Eisai, Eli Lilly, GSK, HLS Therapeutics, Insulet, Medtronic, Merck, MSD, Novo Nordisk, Pfizer, Sandoz, Sanofi, and Vertex; Gian Paolo Fadini: Received grants, honoraria or lecture fees from AstraZeneca, Boehringer, Eli Lilly, Guidotti, Mundipharma, Novartis, Novo Nordisk, Servier, and Sanofi; Pam Kushner: Received honoraria for consulting or advisory boards for AstraZeneca, Bayer, Boehringer Ingelheim, Eli Lilly, Novo Nordisk and VERDIVA; Fabrice Bonnett: No competing interests; Paola Fioretti: Received fees as consultant and speaker for AstraZeneca, Bayer, Boehringer Ingelheim, Eli Lilly and Novo Nordisk; Takashi Kadowaki: Received research grants from Nippon Boehringer Ingelheim Co., Ltd. and Sumitomo Pharma Co., Ltd.; receiving consulting fees from Taisho Pharmaceutical Co., Ltd., Eli Lilly Japan K.K. and Novo Nordisk Pharma Ltd.; receiving honoraria for lectures from Nippon Boehringer Ingelheim Co., Ltd., Sumitomo Pharma Co., Ltd., Teijin Pharma Ltd., MSD Corporation, Eli Lilly Japan K.K., Mitsubishi Tanabe Pharma Corporation, Taisho Pharmaceutical Co., Ltd. and Novo Nordisk Pharma Ltd.; Naresh Kanumilli: No competing interests; Xavier Cos: No competing interests; Thomas Frese: Received payments from Astra Zeneca and Boehringer Ingelheim; Linong Ji: No competing interests; Molly Murton: Employee of Costello Medical; Simon Foulcer: Employee of AstraZeneca and hold associated stock options; Surendra Pentakota: Employee of AstraZeneca and held associated stock options at time of project; Peter Rossing: Received consultancy and\/or speaker fees (to his institution) from Abbott, AstraZeneca, Amgen, Bayer, Boehringer Ingelheim, Eli Lilly, Gilead, Novo Nordisk and Roche; research grants from AstraZeneca, Bayer and Novo Nordisk; study drugs from AstraZeneca, Bayer Lexicon and Novo Nordisk.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}